Newest Impact Factor
1.9
Released June 18, 2026 · Based on 2025 citation data
New this year
Metric year 2025
Released
| Category | Indexes | Quartile |
|---|---|---|
| GENETICS & HEREDITY | ESCI | Q3 |
| PHARMACOLOGY & PHARMACY | ESCI | Q3 |
Rare Disease and Orphan Drugs Journal's newest impact factor is 1.9, released June 18, 2026 and based on 2025 citation data. The journal is listed as JCR Q3 in this Journal Metrics record.
Use this record to check the journal title, ISSN, JCR quartile, CAS block, publisher details, and similar journals before comparing publication venues.
If you searched for Rare Disease and Orphan Drugs Journal impact factor, compare this exact title record with the journal homepage and nearby journals in the same field. That helps avoid mixing this journal with a similarly named title, abbreviation, society series, or outdated metric snippet.
This page is designed for exact-title searches such as Rare Disease and Orphan Drugs Journal impact factor. First confirm that the ISSN and title match this record before using the metric in a journal shortlist or submission decision.
For high-stakes submission decisions, verify the title against the publisher record, Clarivate's Master Journal List or Journal Citation Reports if you have access, and the context in our methodology. Treat the JCR quartile, article volume, and similar journals as supporting context rather than a single-number publication decision.
Ranked #3,675 in Medicine by impact factor and #620 among Q3 Medicine journals. This context helps compare Rare Disease and Orphan Drugs Journal against journals publishing in the same field.
Published 129 papers across the last 5 recorded years with a current impact factor of 1.9.
See if your manuscript fits this journal's recent focus before you commit to a shortlist.